CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Infanrix™-IPV/Hibbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00964028
NCT00964028Phase 3Completed
CompareCT.gov

Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) in Infants

GlaxoSmithKline·interventional·Posted Aug 24, 2009·Updated Jun 6, 2018

In Brief

A Phase 3 clinical trial evaluating Infanrix™-IPV/Hib for Haemophilus Influenzae Type b and 4 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This study will evaluate the safety and reactogenicity of Infanrix-IPV/Hib given as a three-dose primary vaccination course to healthy infants at 2-3-4 or 3-4-5 months of age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHaemophilus Influenzae Type b, Acellular Pertussis, Diphtheria, Tetanus, Poliomyelitis
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 24, 2009
Enrollment StartDec 1, 2009
Primary CompletionApr 12, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.9 years ago

Interventions

Infanrix™-IPV/Hibbiological

Intramuscular, three doses